KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Deferred Taxes: 2009-2025

Historic Deferred Taxes for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Sep 2025 value amounting to $107.0 million.

  • Teva Pharmaceutical Industries' Deferred Taxes rose 301.89% to $107.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.0 million, marking a year-over-year increase of 93.06%. This contributed to the annual value of -$634.0 million for FY2024, which is 100.00% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Deferred Taxes stood at $107.0 million for Q3 2025, which was up 150.71% from -$211.0 million recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Deferred Taxes peaked at $150.0 million during Q4 2022, and registered a low of -$1.1 billion during Q2 2022.
  • For the 3-year period, Teva Pharmaceutical Industries' Deferred Taxes averaged around -$93.4 million, with its median value being -$53.0 million (2024).
  • Data for Teva Pharmaceutical Industries' Deferred Taxes shows a peak YoY increase of 450.00% (in 2022) and a maximum YoY decrease of 6,868.75% (in 2022) over the last 5 years.
  • Teva Pharmaceutical Industries' Deferred Taxes (Quarterly) stood at -$133.0 million in 2021, then skyrocketed by 212.78% to $150.0 million in 2022, then slumped by 78.67% to $32.0 million in 2023, then remained steady at $32.0 million in 2024, then skyrocketed by 301.89% to $107.0 million in 2025.
  • Its last three reported values are $107.0 million in Q3 2025, -$211.0 million for Q2 2025, and $28.0 million during Q1 2025.